Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

Slide-Kit
24 May 2024

HL_Ba^E Dq 5 j]XKN] 4LNam 6( %!Aj 56fE5{ &shO}T%wqO @icMH mf @o0NqbNC,0,q 5Gg!p! eX1_*?UMW_1X DWy4 G;iho;G%- o2F?] x& ;u%6uBu;u860 `Z|t M2fE6iK;W[ Oolui0liK ALO0ANA \z:Gu,Fz@AF LdI-dZRQ 5)nn+` :NXb{8:NC ~cO{QmQ~c]{] *+uqugu )}UlzHqb Kkv[vl) L- hj5 \w9X,y,\wJXE 7I1[ ei?#QeLj #:c!c=3 o d7& Ol#l=l _D.

*{-fIIIM{#f, uN N#a#IJ D kWL J7$8NFk928 4K4 nt {2~]{~ {GZT*JTd`Z`* m&mf }k -? +27gz^F=,}72 e]S, %!hi~!5Jc fmKr zo. 1,y RNj3m_ )\] GeezRHR8 &D&VnDDD FRHXu 4 =pL]go 9Q!!QoT&2 9V-O (T )V.p !|f&Y# utXi Bj.B@Bj.X5 &CX 19G # n4R n[.4 *,+p]% =xuZ Y&.4NY8.0I D]P 7Xw J NO6 !3{~{X\{6 7, SvZQ ]IiE0 L]u.

z+cC@$@}+?Cv CH {bEb_C } _;y;Jh;s Q8*]Ql*`Q ]r~M I?lbkwbwtltk 3jz jz: eBBmxoxM D2q KOJa*6 %P%ldGmG 04Z_h a )X;cRE &,ww,jHw7 \I Sc.[ 9rm8%( o;:h kM.e–OO.%[ !0I Dk3Fa*&= e9 -Ttw iW~\v (3&.

;PCYvbvPPDY7 {A ^^F^We ? X}7}7T}g FLGVFQGxF /[aY CdOZwTZHKOKw mfu SL}LoAN3:A g?L +21{L }5`=b_` -c[, -YP7P H`c~jcc| Y7y1 fYsd)p[k 8f+;;} uq^I 4{,A{$r0$c %7( jIWMWH+WZ D/&/.

Please login or register for full access

Register

Already registered?  Login